Results 71 to 80 of about 18,928 (205)
Safety of Prasugrel in Indian patients – Multicentric registry of 1000 cases
Indian Heart Journal, 2014 Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available.
Upendra Kaul +14 more
doaj +1 more source
Early Mobilization After Pacemaker Implantation
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd +3 more
wiley +1 more source
PLoS ONE, 2015 BackgroundPrasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders,
Tobias Geisler +14 more
doaj +1 more source
Contemporary NSTEMI management: the role of the hospitalist. [PDF]
, 2019 Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event.
Amin, Alpesh +9 more
core +1 more source
P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity [PDF]
, 2014 Background: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein (GP) IIb‐IIIa antagonists, but their combined effect on platelet function and ...
Barnard, Marc R. +5 more
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundProton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism. We sought to understand the comparative effectiveness and safety of prasugrel versus clopidogrel in the context of proton pump inhibitor
Larry R. Jackson +10 more
doaj +1 more source
Reduction in Recurrent Cardiovascular Events with Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes from the TRITON-TIMI 38 Trial [PDF]
, 2011 Aims: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS ...
Antman, Elliott Marshall +8 more
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon +10 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background The efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome and prior myocardial infarction (MI) remain unstudied. We aimed to assess the treatment effect of ticagrelor versus prasugrel according to prior MI
Shqipdona Lahu +20 more
doaj +1 more source
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization [PDF]
, 2012 peer reviewedBACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.
Alexander Parkhomenko +39 more
core +1 more source